ArriVent BioPharma, Inc. (AVBP)

In the past six months, ArriVent BioPharma's stock closed at $23.60 on January 26, 2026, which was 20.57% below its 52-week high. Key events include the first patient dosed in the ALPACCA trial, Hillhouse-affiliated entities selling shares, reporting of Third Quarter 2025 and Full Year 2024 financial results, the appointment of Brent S. Rice as Chief Commercial Officer, and reporting of First Quarter 2025 financial results including an increased net loss and R&D expenses.

As a clinical-stage biopharmaceutical company, ArriVent BioPharma, Inc.'s products are currently in clinical trials and not yet commercialized, so there is no discernible demand seasonality. The demand for its drug development activities is driven by the progression of clinical trials, regulatory milestones, and ongoing research, rather than seasonal consumer patterns.

ArriVent BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on identifying, developing, and commercializing innovative medicines for unmet medical needs in oncology. Their lead product candidate, firmonertinib, is undergoing clinical trials for EGFRm NSCLC, including a pivotal Phase 3 trial. The company is also developing ARR-217 for gastrointestinal cancers and ARR-002 for solid tumors, and engages in strategic collaborations with global biotech firms.

ArriVent BioPharma, Inc. is headquartered in Newtown Square, Pennsylvania, United States. The company maintains a global network to access drug candidates from various development stages, including those originating from China and other emerging biotech hubs, to globalize medicines for patients with unmet medical needs.

ArriVent BioPharma's brand reputation is generally positive, driven by its clinical pipeline progress and analyst sentiment. The company has a consensus rating of "Moderate Buy" with a potential upside of 88.10%. The advancement of firmonertinib and the development of other therapeutics contribute positively to its reputation. Strategic collaborations also enhance its standing. Financial reports have shown increased net losses and R&D expenses, which are common for clinical-stage biotech firms.

ArriVent BioPharma, Inc. has 194 institutional owners and shareholders, holding a total of 39,846,894 shares. Major institutional owners include Hillhouse Capital Advisors, Ltd., Infinitum Asset Management, Llc, and Suvretta Capital Management, Llc. As of September 30, 2025, Hillhouse Investment Management, Ltd. held 10.86% of the company's shares, Infinitum Asset Management, Llc held 9.37%, and Suvretta Capital Management, LLC held 8.97%.